J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...
In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...
In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...
—Shared pathogenesis between atopic dermatitis, vitiligo, and alopecia areata supports a unified approach that targets these common mechanisms, promising better treatment options for these ...
Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathology SYX-5219 is a first-in-class oral PKM2 modulator designed to drive ...
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (TTRX) (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease ...
Spa treatment. Image by IQP - CC BY-SA 3.0, Spa treatment. Image by IQP - CC BY-SA 3.0, Atopic dermatitis (AD) is experiencing a shift in treatment management with recent drug approvals that address ...
ORLANDO -- Novel interleukin (IL)-2 receptor agonist and regulatory T-cell (Treg) proliferator rezpegaldesleukin improved control of atopic dermatitis with potential incidental benefit for comorbid ...
Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback